Special Issue

Topic: Resistance to Cancer Immunotherapy: Mechanisms, Advances, Challenges and Opportunities
Guest Editor(s)
Dr. Jordi Rodon
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Special Issue Introduction
Despite the clinical benefit obtained with current cancer immunotherapy, there is a large group of patients who do not respond or respond poorly to current therapies. In fact, some even show hyperprogression once immunotherapy is started. Underlying mechanisms of resistance are thought to be driving this lack of response to immunotherapy.
In the present Special Issue, the various concepts of resistance mechanisms will be summarized. This will include mechanisms of primary resistance, various barriers to immunotherapies, the selection of tumour clones that lead to resistance and finally the molecular changes within tumour cells rendering them resistant to therapy.
An important pillar for studying resistance is the available tools to detect and monitor resistance in patients. Biomarker tests that can assess emerging or pre-existing intrinsic or extrinsic factors leading to resistance are perhaps more than ever needed to direct physicians towards seeking novel therapies.
This Special Issue aims to compile a collection of updated research, review and expert opinion articles on resistance mechanisms, the available strategies to detect such developments and propose potential novel therapeutic approaches.
Sub-topics:
Concept of resistance to immunotherapy
Potential mechanisms of resistance to immunotherapy
Targets for overcoming resistance to immunotherapy
In the present Special Issue, the various concepts of resistance mechanisms will be summarized. This will include mechanisms of primary resistance, various barriers to immunotherapies, the selection of tumour clones that lead to resistance and finally the molecular changes within tumour cells rendering them resistant to therapy.
An important pillar for studying resistance is the available tools to detect and monitor resistance in patients. Biomarker tests that can assess emerging or pre-existing intrinsic or extrinsic factors leading to resistance are perhaps more than ever needed to direct physicians towards seeking novel therapies.
This Special Issue aims to compile a collection of updated research, review and expert opinion articles on resistance mechanisms, the available strategies to detect such developments and propose potential novel therapeutic approaches.
Sub-topics:
Concept of resistance to immunotherapy
Potential mechanisms of resistance to immunotherapy
Targets for overcoming resistance to immunotherapy
Keywords
Immunotherapy resistance, potential mechanisms of immunotherapy resistance, targets for overcoming immunotherapy resistance, immune checkpoints inhibitors
Submission Deadline
30 Apr 2023
Submission Information
For Author Instructions, please refer to https://oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR221026
Submission Deadline: 30 Apr 2023
Contacts: Belinda Zhang, Assistant Editor, Belinda@cdrjournal.com
Published Articles
Open Access Review
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
This article belongs to the Special Issue Resistance to Cancer Immunotherapy: Mechanisms, Advances, Challenges and Opportunities
Cancer Drug Resist 2023;6:768-87.
DOI: 10.20517/cdr.2023.58
Available online: 16 Nov 2023
Open Access Review
Unlocking antitumor immunity with adenosine receptor blockers
This article belongs to the Special Issue Resistance to Cancer Immunotherapy: Mechanisms, Advances, Challenges and Opportunities
Cancer Drug Resist 2023;6:748-67.
DOI: 10.20517/cdr.2023.63
Available online: 24 Oct 2023
Open Access Review
Drug resistance in glioblastoma: from chemo- to immunotherapy
This article belongs to the Special Issue Resistance to Cancer Immunotherapy: Mechanisms, Advances, Challenges and Opportunities
Cancer Drug Resist 2023;6:688-708.
DOI: 10.20517/cdr.2023.82
Available online: 10 Oct 2023
Open Access Review
Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia
This article belongs to the Special Issue Resistance to Cancer Immunotherapy: Mechanisms, Advances, Challenges and Opportunities
Cancer Drug Resist 2023;6:674-87.
DOI: 10.20517/cdr.2023.39
Available online: 25 Sep 2023
Open Access Review
A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer
This article belongs to the Special Issue Resistance to Cancer Immunotherapy: Mechanisms, Advances, Challenges and Opportunities
Cancer Drug Resist 2023;6:656-73.
DOI: 10.20517/cdr.2023.48
Available online: 24 Sep 2023
Open Access Review
Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
This article belongs to the Special Issue Resistance to Cancer Immunotherapy: Mechanisms, Advances, Challenges and Opportunities
Cancer Drug Resist 2023;6:611-41.
DOI: 10.20517/cdr.2023.60
Available online: 3 Sep 2023